Overview

A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)

Status:
NOT_YET_RECRUITING

Trial end date:
2025-07-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of intravenous infusions of burfiralimab (hzVSF-v13) when added to Disease-Modifying Antirheumatic Drug (DMARD) treatment as Standard of Care (SOC) in participants with moderate to severe Rheumatoid Arthritis (RA).

Phase:

PHASE2

Details

Lead Sponsor:

ImmuneMed, Inc.

Treatments:

Standard of Care